Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 109 participants.
Also called NCT06448962
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 109 participants
- Sponsor
- Registry
-
NCT06448962
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT06448962. Randomized; double masking; primary purpose treatment. Start 2020-10-22 (actual); primary completion 2021-11-22 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022
- Condition
- Hypertension, Essential
- Condition
- Primary Hypercholesterolemia
- Intervention (Drug)
- AD-2021
- Intervention (Drug)
- AD-2022
- Intervention (Drug)
- AD-2021 Placebo
- Intervention (Drug)
- AD-2022 Placebo
- Lead sponsor
- Addpharma Inc.
Record details
- Record id
cardio:ct-nct06448962- Content hash
4dca2a4a453c17670f84865bdeb6dca1c165b88ca8e9df8710119d34503a088b